Details

Autor(en) / Beteiligte

• Barbier, Emilie
• François, Eric
• Michel, Pierre
• Rougier, Philippe
• Seitz, Jean-François
• Aouakli, A.
• Bedjaoui, A.
• Botton, A.
• Cadier-Lagnes, A.
• Hollebecque, A.
• Lemaire, A.
• Marre, A.
• Villing, A.L.
• Denis, B.
• Becht, C.
• Bineau, C.
• Borel, C.
• Buffet, C.
• Cornila, C.
• Couffon, C.
• Locher, C.
• Rebischung, C.
• Sarda, C.
• Auby, D.
• Baudet-Klepping, D.
• Besson, D.
• Cleau, D.
• Festin, D.
• Genet, D.
• Peré-Vergé, D.
• Pillon, D.
• Smith, D.
• Dorval Danquechin, E.
• Maillard, E.
• Mitry, E.
• Suc, E.
• Zrihen, E.
• Pariente, E.A.
• Dewaele, F.
• Di Fiore, F.
• Husseini, F.
• Kikolski, F.
• Petit-Laurent, F.
• Zerouala-Boussaha, F.
• Caroli-Bosc, F.X.
• Boilleau-Jolimoy, G.
• Medinger, G.
• Graber, I.
• Charneau, J.
• Cretin, J.
• Deguiral, J.
• Lacourt, J.
• Meunier, J.
• Vincent, J.
• Volet, J.
• Barbare, J.C.
• Paitel, J.F.
• Raoul, J.L.
• Gornet, J.M.
• Aucouturier, J.P.
• Barbieux, J.P.
• Plachot, J.P.
• Ramain, J.P.
• Spano, J.P.
• Bouhier-Leporrier, K.
• Cany, L.
• Rob, L.
• Baconnier, M.
• Benchalal, M.
• Combe, M.
• Duluc, M.
• Giovannini, M.
• Mabro, M.
• Ramdani, M.
• Tissot, M.
• Clavero-Fabri, M.C.
• Gouttebel, M.C.
• Kaminsky, M.C.
• Stremsdoerfer, N.
• Burtin, P.
• Cassan, P.
• Claudé, P.
• Couzigou, P.
• Geoffroy, P.
• Godeau, P.
• Hammel, P.
• Novello, P.
• Prost, P.
• Ruszniewski, P.
• Texereau, P.
• Coriat, R.
• Nasca, S.
• Fratte, S.P.
• Mansourbakht, T.
• Walter, T.
• Derias, V.
• Jestin Le Tallec, V.
• Sebbagh, V.
• Adhoute, X.
• Becouarn, Y.

Titel

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Ist Teil von

• European journal of cancer (1990), 2018-07, Vol.98, p.1-9

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• Previous studies showed that high and low body mass index (BMI) was associated with worse prognosis in early-stage colorectal cancer (CRC), and low BMI was associated with worse prognosis in metastatic CRC (mCRC). We aimed to assess efficacy outcomes according to BMI. A pooled analysis of individual data from 2085 patients enrolled in eight FFCD first-line mCRC trials from 1991 to 2013 was performed. Comparisons were made according to the BMI cut-off: Obese (BMI ≥30), overweight patients (BMI ≥ 25), normal BMI patients (BMI: 18.5–24) and thin patients (BMI <18.5). Interaction tests were performed between BMI effect and sex, age and the addition of antiangiogenics to chemotherapy. The rate of BMI ≥25 patients was 41.5%, ranging from 37.6% (1991–1999 period) to 41.5% (2000–2006 period) and 44.8% (2007–2013 period). Comparison of overweight patients versus normal BMI range patients revealed a significant improvement of median overall survival (OS) (18.5 versus 16.3 months, HR = 0.88 [0.80–0.98] p = 0.02) and objective response rate (ORR) (42% versus 36% OR = 1.23 [1.01–1.50] p = 0.04) but a comparable median progression-free survival (PFS) (7.8 versus 7.2 months, HR = 0.96 [0.87–1.05] p = 0.35). Subgroup analyses revealed that overweight was significantly associated with better OS in men. OS and PFS were significantly shorter in thin patients. Overweight patients had a prolonged OS compared with normal weight patients with mCRC. The association of overweight with better OS was only observed in men. The pejorative prognosis of BMI <18.5 was confirmed. •Body mass index of patient enrolled in clinical trial increases across the time period.•Overweight patients had a prolonged overall survival compared with normal weight patients.•The association of overweight with better OS was only observed in men.•Thin patients had a worst overall survival compare to normal weight patients.